Global Individual Case Safety Reports (ICSR)

Reporting and Submissions

ICSR Reporting

Ensuring patient safety is the most important component of a pharmacovigilance (PV) system. Therefore, all pharmaceutical and biotechnology companies are required to identify, collect, and process Individual Case Safety Reports (ICSRs) in a systematic and robust manner, and report to regulatory authorities in accordance with strict requirements and timelines.

ProPharma recognizes the critical nature of accurate and on-time submissions to regulatory authorities, Institutional Review Boards (IRBs), Ethics Committees (ECs), and investigator sites.

We perform ICSR submissions including MedWatch, CIOMS I, E2B(R2), and E2B(R3) reports for various product types including approved and non-approved drugs, biologics, devices, vaccines, dietary supplements, cosmetics, homeopathic products, and natural health products.

Business professionals smiling at a desk reviewing data
Hands gesturing over data and charts

ProPharma's ICSR Workflow

ICSRs are exchanged with clients and Sponsors for review and comment before the final submission, if requested. Clients and Sponsors also maintain oversight of case processing and reporting activities ahead of submission via Case Explorer, a read-only application that allows for real-time database queries and review of information within individual cases.

Clients and Sponsors who wish to maintain oversight of case processing within the safety database itself may also do so via read-only access as part of individual user implementation and security procedures.

ICSR Submissions & Reporting

Ensure compliance and patient safety with ProPharma's expert ICSR processing and reporting. Our comprehensive pharmacovigilance services streamline your safety data management, ensuring accuracy and efficiency.

ICSR Compliance

QPPV office icon

Monthly Compliance Metrics

Each month, compliance metrics are generated from submission records in the safety database for all pharmacovigilance and clinical safety programs and shared with all...

Read More

Monthly Compliance Metrics

Each month, compliance metrics are generated from submission records in the safety database for all pharmacovigilance and clinical safety programs and shared with all interested clients.

Read Less
Compliance

+99% Compliance Submission Rate

ProPharma is proud to post a greater than 99% compliance rate, successfully submitting over 2,000 ICSRs per month to regulatory authorities and business partners on...

Read More

+99% Compliance Submission Rate

ProPharma is proud to post a greater than 99% compliance rate, successfully submitting over 2,000 ICSRs per month to regulatory authorities and business partners on behalf of post-marketing pharmacovigilance clients and clinical safety Sponsors.

Read Less

Frequently Asked Questions about ICSRs

Medical Information icon

What is an Individual Case Safety Report (ICSR)?

What is an Individual Case Safety Report (ICSR)?

Expert Witness icon

What are the FDA requirements for an ICSR?

What are the FDA requirements for an ICSR?

Product compliant intake icon

What are the MHRA/EMA requirements for an ICSR?

What are the MHRA/EMA requirements for an ICSR?

What is an Individual Case Safety Report (ICSR)?

An Individual Case Safety Report (ICSR) is a document that captures information needed to report one or more suspected adverse reactions to a medical product that occur in a single patient at a specific point in time. ICSRs are used to support the monitoring and evaluation of the safety and effectiveness of medical products, such as drugs, biologics, vaccines, devices, and tobacco products. ICSRs are also used to identify potential signals of new or emerging safety issues, or changes in the known safety profile of a product.

health-care-worker-wearing-headset-working-on-laptop-ss-1829353274-650x425

What are the FDA requirements for an ICSR?

The FDA requirements for an ICSR are as follows:

  • An ICSR should include the following information:
    • Patient information, such as patient identification code and age at the time of adverse drug experience.
    • Adverse event information, such as outcome attributed to adverse drug event.
    • Suspect medical product information, such as name. 
    • Initial reporter information, such as name, address, and telephone number.
    • Applicant information, as defined in section 760 (b) of the FD&C Act.
  • Submitted electronically using the ISO ICSR/ ICH E2B (R2/R3) format and related ISO standard terminology for pharmaceutical form and route of administration.
  • Clinical trial Suspected Unexpected Serious Adverse Reactions (SUSARs) are submitted within 7 days for fatal/life threatening reports and 15 days for all other serious reports.
  • Post marketed serious ICRS are submitted within 15 days and within 90 days for non-serious EU ICSRs, according to the regulatory reporting guidelines.
  • Submitted to the FDA Adverse Event Reporting System (FAERS) or to the appropriate FDA center, depending on the product type and submission method.
  • An ICSR should follow the guidance documents, implementation guides, specifications, schema files, and validation procedures published by the FDA for electronic submission of ICSRs.
Business professionals discussing data around a conference table

What are the MHRA/EMA requirements for an ICSR?

The EMA requirements for an ICSR are as follows:

  • Per the GVP module VI requirements this must include an identifiable reporter, an identifiable patient, adverse reaction information, and a suspect medicinal product.
  • Should be submitted electronically using the ISO ICSR/ICH E2B (R3) format and related ISO standard terminology for pharmaceutical form and route of administration.
  • Clinical trial Suspected Unexpected Serious Adverse Reactions (SUSARs) are submitted within 7 days for fatal/life threatening reports and 15 days for all other serious reports.
  • Post marketed serious ICRS are submitted within 15 days and within 90 days for non-serious ICSRs, according to the regulatory reporting guidelines.
  • Submitted to the applicable regulatory authority (e.g. EudraVigilance database or MHRA ICSR portal)where the suspected adverse reaction occurred, depending on the marketing authorization procedure and the origin of the ICSR.
Business and healthcare professionals smiling around charts

News & Insights

FDA Releases Final ICH M13A Guidance Document

December 10, 2024

FDA Releases Final ICH M13A Guidance Document

FDA recommendations for conducting BE studies, efficiency improvements in global drug development, and how ProPharma can assist with your regulatory needs.

The Evolving Landscape of Quality Management Systems in the Life Sciences Industry

December 9, 2024

The Evolving Landscape of Quality Management Systems in the Life Sciences Industry

Discover the evolving landscape of Quality Management Systems in the life sciences industry and how to navigate modern regulatory challenges.

Pre-Approval Inspection (PAI) Readiness is Easy, Right?

December 5, 2024

Pre-Approval Inspection (PAI) Readiness is Easy, Right?

Ensure your product's success with ProPharma's expert guidance on PAI readiness, from remediation tasks to regulatory filing support.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

News & Insights

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

Previous Post Arrow Next Post Arrow
ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Previous Award Arrow Next Award Arrow
FDA Releases Final ICH M13A Guidance Document

December 10, 2024

FDA Releases Final ICH M13A Guidance Document

FDA recommendations for conducting BE studies, efficiency improvements in global drug development, and how ProPharma can assist with your regulatory needs.

The Evolving Landscape of Quality Management Systems in the Life Sciences Industry

December 9, 2024

The Evolving Landscape of Quality Management Systems in the Life Sciences Industry

Discover the evolving landscape of Quality Management Systems in the life sciences industry and how to navigate modern regulatory challenges.

Pre-Approval Inspection (PAI) Readiness is Easy, Right?

December 5, 2024

Pre-Approval Inspection (PAI) Readiness is Easy, Right?

Ensure your product's success with ProPharma's expert guidance on PAI readiness, from remediation tasks to regulatory filing support.

Previous Post Arrow Next Post Arrow
Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

Previous Resource Arrow Next Resource Arrow